Highlander Partners’s Reata Pharmaceuticals RETA Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2022
Q1
– Sell
-27,600
Closed -$728K – 26
2021
Q4
$728K Hold
27,600
– – 0.89% 17

Other funds holding RETA

Highlander Partners's RETA Position: Q1 2022 in Review

Highlander Partners sold out of Reata Pharmaceuticals (RETA) in Q1 2022, closing a stake of 27,600 shares — an estimated $728K sold.

Highlander Partners first reported a position in RETA in Q4 2021 and held it in 1 quarter. The position peaked at $728K in Q4 2021. 147 funds tracked by Wall St. Rank hold RETA as of Q1 2022.

  • Highlander Partners reported no remaining Reata Pharmaceuticals position as of Q1 2022 after selling out during the quarter.
  • Highlander Partners sold 27,600 Reata Pharmaceuticals shares in Q1 2022, an estimated $728K.
  • Highlander Partners first reported a position in Reata Pharmaceuticals in Q4 2021 and held it in 1 quarter.
  • Highlander Partners's Reata Pharmaceuticals position peaked at $728K in Q4 2021.
  • 147 funds tracked by Wall St. Rank held Reata Pharmaceuticals as of Q1 2022.

Based on Highlander Partners's 13F filing for Q1 2022, filed 27 Apr 2022.